Swetlana Adamsky

Swetlana Adamsky's work experience is as follows:

- Head, Global Metabolic Programs at Orgenesis Inc. since July 2020 (present)

- Senior Director of Translational Research at Quark Pharmaceuticals from May 2017 to July 2020

- Director of Translational Research at Quark Pharmaceuticals Inc from June 2007 to May 2017

- CEO at MS Vision from May 2006 to May 2007

- Staff Scientist at Weizmann Institute of Science from August 2004 to April 2006

Swetlana Adamsky's education history begins in 1986 when they enrolled at The Russian State Medical University. Swetlana pursued degrees in Neurology and Medical Cybernetics, completing their studies in 1993 with an M.D., MSc. degree. Following this, they attended the Weizmann Institute of Science from 1996 to 2001 where they obtained a Ph.D. in Biochemistry. Swetlana further continued their academic pursuits at the same institute from 2000 to 2004 as a Postdoctoral Fellow, focusing on various areas including Metabolic Diseases, Lysosomal Storage Diseases, Neurobiology, and Breast Cancer.